Synergy as defined by a combination index of <1 via the Chou-Talalay method between KAN0441571C and venetoclax was demonstrated in 8 SCLC cell lines. We have shown that ROR1 inhibition is synergistic with BCL2 inhibition in SCLC models and shows promise as a novel therapeutic target in SCLC.

over 3 years ago

Journal • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)

BCL2 expression

Venclexta (venetoclax) • KAN571

4years

[VIRTUAL] Predicting ROR1/BCL2 Combination Targeted Therapy of Small Cell Carcinoma of the Lung (IASLC-WCLC 2020)

Synergy as defined by a combination index of <1 via the Chou-Talalay method between KAN0441571C and venetoclax was demonstrated in all 8 SCLC cell lines. Conclusion We have demonstrated that ROR1 inhibition is synergistic with BCL2 inhibition in SCLC models and shows promise as a novel therapeutic target in SCLC.

4 years ago

IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)

BCL2 expression

Venclexta (venetoclax) • KAN571